Alexander B. Karol

Alexander B. Karol

Auto-generated profile, based on publicly available information

Alexander B. Karol

Division of Hematology/Oncology, Department of Medicine Tisch Cancer Institute Icahn School of Medicine at Mount Sinai New York New York USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2019 in Blood Advances
Verified
Journal Article
Closed access
HSHrishikesh K. Srinagesh
Hrishikesh K. Srinagesh
UÖUmut Özbek
Umut Özbek
UKUrvi Kapoor
Urvi Kapoor
FAFrancis Ayuk
Francis Ayuk
MAMina Aziz
Mina Aziz
JFJames L. M. Ferrara
James L. M. Ferrara
Key Points: The MAGIC algorithm probability, computed from 2 serum biomarkers, predicts mortality in all GVHD grades after 4 weeks of treatment. Dynamic changes in the MAGIC algorithm probability occur within all biomarker risk groups and can guide therapy.

12 October 2022 in Endocrine Practice
Verified
Journal Article
Closed access
AKAlexander B. Karol
Alexander B. Karol
GOGrenye O'MAlley
Grenye O'MAlley
RFReshmitha Fallurin
Reshmitha Fallurin
CLCarol J. Levy
Carol J. Levy

3 July 2024 in Immunotherapy
Verified
Journal Article
Closed access
AKAlexander B Karol
Alexander B Karol
YFYu Fujiwara
Yu Fujiwara
TDTyler D'OVidio
Tyler D'OVidio
EBElena Baldwin
Elena Baldwin
HJHimanshu Joshi
Himanshu Joshi
MGMatthew D Galsky
Matthew D Galsky
Background: Tumor-promoting inflammation and inflammatory cytokines are linked to immune checkpoint blockade (ICB) resistance. Methods: We assessed the associations between pre-treatment Interleukin-6 (IL-6), Interleukin-8 (IL-8) levels and on-treatment changes in IL-6, IL-8 and C-reactive protein (CRP) with ICB trial end points. Results: 27 studies representing 6,719 patients were included. Low pre-treatment IL-6 levels were associated with improved objective response rate (ORR) (odds ratio (OR) = 0.31 [0.18-0.55]) and better progression-free survival (PFS) (hazard ratio (HR) = 0.59 [0.48-0.72]) and overall survival (OS) [95% confidence interval (CI)] (HR = 0.42 [0.35-0.50]). Low pre-treatment IL-8 levels were associated with improved ORR (OR = 0.47 [0.36-0.61]) and better PFS (HR = 0.65 [0.58-0.74]) and OS (HR = 0.44 [0.39-0.51]). On-treatment decline in CRP was associated with improved ORR (OR = 0.18 [0.11-0.20]), PFS (HR = 0.40 [0.31-0.91]) and OS (HR = 0.48 [0.40-0.58]). Conclusion: Peripheral blood cytokines warrant further evaluation as enrichment and pharmacodynamic biomarkers for strategies targeting tumor-promoting inflammation.

3 September 2024 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
AKAlexander B. Karol
Alexander B. Karol
RPRodrigo Paredes
Rodrigo Paredes
YFYu Fujiwara
Yu Fujiwara
AAAnna Argulian
Anna Argulian
HJHimanshu Joshi
Himanshu Joshi
MGMatthew D. Galsky
Matthew D. Galsky
Kidney function is frequently impaired in patients with cancer due to preexisting chronic kidney disease, cancer-associated factors, and prior anticancer treatments. Given these multifactorial insults, accurate assessment of kidney function is critical to determining patient eligibility for clinical trial enrollment. Measurement of the glomerular filtration rate (GFR) using clearance of exogenous markers provides the most accurate measure of kidney function but is not practical clinically. Although serum creatinine (sCr) level alone has been used to estimate kidney function, it can be influenced by non-GFR physiologic determinants, such as sarcopenia, and nephrology and oncology organization guidelines recommend against using sCr level alone.1 Several equations incorporating clinical and demographic variables have been developed to improve the estimation of kidney function.2 Recently, there have been calls for harmonization of most aspects of cancer clinical trial eligibility to foster feasibility, inclusivity, comparability, and generalizability.3 We sought to understand the landscape of approaches used to estimate kidney function for contemporary cancer clinical trial eligibility.

26 September 2025 in Cancer
Verified
Journal Article
Closed access
AKAlexander B. Karol
Alexander B. Karol
RFRodrigo Paredes de la Fuente
Rodrigo Paredes de la Fuente
AAAnna Argulian
Anna Argulian
HJHimanshu Joshi
Himanshu Joshi
LWLexi Weintraub
Lexi Weintraub
MGMatthew D. Galsky
Matthew D. Galsky

1 February 2026 in JCO Global Oncology
Verified
Journal Article
Closed access
RFRodrigo Paredes de la Fuente
Rodrigo Paredes de la Fuente
AKAlexander B. Karol
Alexander B. Karol
AMAnneliese Markus
Anneliese Markus
AAAnna Argulian
Anna Argulian
ROReo Omori
Reo Omori
MGMatthew D. Galsky
Matthew D. Galsky
PURPOSE: Latin America (LATAM), home to over 650 million people, remains under-represented in global oncology trials despite a growing cancer burden. This study aimed to evaluate the evolution of LATAM participation in phase III oncology trials over the past decade, with a focus on site distribution, cancer types studied, therapeutic classes investigated, and demographic reporting. METHODS: We conducted a cross-sectional analysis of global phase III oncology trials registered on ClinicalTrials.gov between January 1, 2013, and December 31, 2022. Trials were included if they studied anticancer therapies and listed at least one LATAM site. We extracted data on trial geography, cancer type, treatment modality, control group, and Hispanic ethnicity reporting. Trends in proportional regional site representation and therapy class were assessed using the Mann-Kendall trend test. RESULTS: A total of 172 phase III trials with LATAM sites were identified, representing 2,609 of 29,718 global sites (8.8%). Brazil (45.8%), Argentina (18.6%), and Mexico (13.0%) accounted for over 75% of LATAM trial sites. LATAM's proportional site representation increased modestly from 7.1% in 2013 to 9.3% in 2021 (Bonferroni-adjusted P = .040), but no individual country showed a statistically significant increase. The most frequently studied cancers were lung (26.7%), breast (22.1%), and genitourinary (16.3%). Targeted therapies (42.4%) and immunotherapies (33.1%) dominated, whereas hormone therapy declined over time. Hispanic ethnicity was reported in only 61.6% of trials, with no improvement over time. CONCLUSION: Although LATAM's participation in global oncology trials has increased, it remains geographically concentrated and demographically under-reported. Structural and policy efforts are needed to improve trial equity and align research with regional cancer burdens.